2023版在检测的方法选择、适用人群、定量标准等多个方面进行了优化和更新,更加符合当前的科学证据和临床实践情况。本版准则全面系统地反映了十余年来DM临床检验领域的进步,为DM的筛查、定量监测、分类诊断提供了更精确和完善的指导方案。 此外,本次更新也提出了一些观念上的革新,比如“24小时尿蛋白定量不应该用于临床而应该用于科研”,以此条建议为例,目前虽未得到大样本随机对照研究的支持,但专家共识认为其可以反映当前最佳的临床实践经验,仍然具备一定的推荐价值,读者阅读指南时应充分考虑到这一方面。 参考文献:[1] Sacks D B, Bruns D E, Goldstein D E, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus[J]. Clinical chemistry, 2002, 48(3): 436-472.[2] Sacks D B, Arnold M, Bakris G L, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus[J]. Clinical chemistry, 2011, 57(6): e1-e47.[3] Sacks D B, Arnold M, Bakris G L, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus[J]. Diabetes Care, 2023.[4] American Diabetes Association Professional Practice Committee, American Diabetes Association Professional Practice Committee:. 11. Chronic kidney disease and risk management: Standards of Medical Care in Diabetes—2022[J]. Diabetes care, 2022, 45(Supplement_1): S175-S184.[5] Metzger B E, Lowe L P, Dyer A R, et al. Hyperglycemia and adverse pregnancy outcomes[J]. Obstetric Anesthesia Digest, 2009, 29(1): 39-40.